Skip to main content

Advertisement

Log in

Practice patterns in patients at risk for glucocorticoid-induced osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Patients suffering from chronic inflammatory conditions often take glucocorticoid medications over long periods of time. More than a million patients in the United States receive these agents each year. One of the most serious side effects of this treatment is glucocorticoid-induced osteoporosis (GIOP). This study characterized glucocorticoid use and osteoporosis screening and treatment patterns within a large U.S. health maintenance organization (HMO). This retrospective cohort study ( n =3,031) used the HMO’s electronic medical record and databases to identify patients who were dispensed the equivalent of >5 mg of prednisone per day for at least 90 days from January 2000 through December 2001. It assessed the primary outcomes, the percent who received a bone mineral density (BMD) measurement from January 1996 through 6 months after the index glucocorticoid prescription and the percent dispensed an osteoporosis medication within 6 months before or after the index glucocorticoid prescription. The participants’ mean age was 61.4 years, 60% were women, and the mean daily dose of corticosteroids was 20.0 mg of prednisone equivalents. The most frequent diagnoses associated with glucocorticoid use were chronic obstructive pulmonary disease, 25.8%; asthma, 21.4%; rheumatoid arthritis, 17.2%. Overall, only 9.8% of the population received a BMD measurement—13% of women and 4.9% of men; 38% were dispensed osteoporosis medications—57.1% of women and 8.9% of men; only 14.5% received treatment with antiresorptive medications other than hormone replacement therapy—18.3% of women and 8.9% of men. Our study found that a substantial proportion of patients receiving long-term glucocorticoid therapy did not receive BMD measurement or preventive therapy for osteoporosis, as recommended in GIOP practice guidelines. Future research should focus on understanding barriers to GIOP identification and facilitating osteoporosis management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lukert BP (1999) Glucocorticoid and drug-induced osteoporosis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams and Wilkins, Philadelphia, pp 278–282

  2. Rackoff PJ, Rosen CJ (1998) Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 12:477–484

    PubMed  Google Scholar 

  3. American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39:1791–1801

    PubMed  Google Scholar 

  4. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  5. Sambrook PN (2000) Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 15:1645–1649

    PubMed  Google Scholar 

  6. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM et al (1998) A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292

    Article  PubMed  Google Scholar 

  7. National Osteoporosis Foundation (2000) Physicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC

  8. Osteoporosis Task Force, American Association of clinical Endocrinologists (1996) AACE clinical practice guideline’s for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 2:157–171

    Google Scholar 

  9. Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M (2003) Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 85-A:2294–2302

    Google Scholar 

  10. Feldstein AC, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: A gap in evidence-based practice guideline. Arch Intern Med 163:2165–2172

    Article  PubMed  Google Scholar 

  11. Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E et al (2001) Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 161:1322–1327

    Article  PubMed  Google Scholar 

  12. Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32–36

    Article  PubMed  Google Scholar 

  13. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: Rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142

    Article  PubMed  Google Scholar 

  14. Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305

    PubMed  Google Scholar 

  15. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344–346

    PubMed  Google Scholar 

  16. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105–111

    Article  PubMed  Google Scholar 

  17. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503

    Article  PubMed  Google Scholar 

  18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    PubMed  Google Scholar 

  19. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299

    PubMed  Google Scholar 

  20. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013

    PubMed  Google Scholar 

  21. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387

    Article  PubMed  Google Scholar 

  22. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318

    Article  PubMed  Google Scholar 

  23. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S et al (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 83:1128–1133

    Article  PubMed  Google Scholar 

  24. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211

    Article  PubMed  Google Scholar 

  25. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285

    Article  PubMed  Google Scholar 

  26. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM et al (2003) Central challenges facing the national clinical research enterprise. JAMA 289:1278–1287

    Article  PubMed  Google Scholar 

  27. Simonelli C, Killeen K, Mehle S, Swanson L (2002) Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 77:334–338

    PubMed  Google Scholar 

  28. Garfield FB, Garfield JM (2000) Clinical judgment and clinical practice guidelines. Int J Technol Assess Health Care 16:1050–1060

    Article  PubMed  Google Scholar 

  29. Shiffman RN, Liaw Y, Brandt CA, Corb GJ (1999) Computer-based guideline implementation systems: a systematic review of functionality and effectiveness. J Am Med Inform Assoc 6:104–114

    PubMed  Google Scholar 

  30. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556

    PubMed  Google Scholar 

  31. Majumdar SR, Kim N, Colman I, Chahal AM, Raymond G, Jen H et al (2005) Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. Arch Intern Med 165:905–909

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the contributions and review by Thomas Weiss, PhD, and Ya Ting Chen, PhD. We also would like to acknowledge the contributions of Debra Burch for the preparation of the manuscript and Martha Swain for editorial assistance and manuscript preparation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adrianne C. Feldstein.

Additional information

This study was supported by a research consulting agreement through Merck & Co., Inc.

Appendix

Appendix

THe ICD-9-CM codes used for diagnoses associated with glucocorticoid use and common comorbidities are presented in

Inlinetable a Diagnoses associated with glucocorticoid use

inlinetable a.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldstein, A.C., Elmer, P.J., Nichols, G.A. et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16, 2168–2174 (2005). https://doi.org/10.1007/s00198-005-2016-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-005-2016-z

Keywords

Navigation